Navigation Links
Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions of ApoC-III and Triglycerides in Patients With High Triglycerides Taking Fibrates
Date:7/22/2013

nd trends toward improvements in insulin sensitivity, suggest that ISIS-APOCIIIRx could have a broad therapeutic profile in addition to triglyceride lowering for patients with severely high triglycerides.  We are also pleased with the data reported today. They demonstrate that ISIS-APOCIIIRx is additive to fibrates with robust reductions of apoC-III and triglycerides," said Richard Geary, Ph.D., senior vice president of development at Isis.  "We look forward to sharing the results from our ongoing Phase 2 study evaluating ISIS-APOCIIIRx as a monotherapy in patients with severely high triglycerides.  In this study, we hope to show that treatment with ISIS-APOCIIIRx in patients with severely high triglycerides also produces significant effects on apoC-III, triglycerides and HDL-C.  Following completion of the Phase 2 program, we plan to discuss our Phase 3 plans with regulators and move rapidly into a Phase 3 program next year in patients with severely high triglycerides (greater than 880 mg/dL)." 

ISIS-APOCIIIRx is an antisense drug intended to treat patients with severely high triglycerides either as a single agent or in combination with other triglyceride-lowering agents.  ISIS-APOCIIIRx targets apoC-III, a gene produced in the liver that plays a central role in the regulation of serum triglycerides.  Humans who do not produce apoC-III have lower levels of triglycerides and lower instances of cardiovascular disease.  In clinical studies, patients with lower levels of apoC-III and triglycerides exhibit lower cardiovascular event rates.  Humans with elevated levels of apoC-III have increased dyslipidemia associated with multiple metabolic abnormalities, such as insulin resistance and/or metabolic syndrome.  In addition, the prevalence of type 2 diabetes is increased in patients with elevated triglycerides.Conference
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced ... Cytogenetics Market 2014-2018" report to their ... ,Molecular Cytogenetics involves the study of chromosomes ... and functions of genes and chromosomes. It ...
(Date:9/18/2014)... Sept. 18, 2014  LABSCO, the leading ... and products to hospitals, physician office laboratories ... amended distributorship agreement with Sysmex America.  This ... instruments, including the Sysmex XS-1000 i ™, ... and XN-Series Automated Hematology Analyzers. ...
(Date:9/18/2014)... -- According to the new research ... Warming & Cooling), Application (Acute & Perioperative Care, ... & Paramedical Staff) - Global Forecasts & Trends ... global Temperature Management Market over the forecast period ... to reach $2.5 Billion by 2019 at CAGR ...
Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4
... EyeScience(TM) ( www.eyescience.com ) announced today that ... and Dry Eye Formula(TM) are the only ... from their offices and through mass market retail. This announcement ... growing demand for the most complete eye vitamins available for ...
... (Nasdaq: HOLX ) today announced that Jack Cumming, Chairman, ... London on Tuesday, December 1, 2009, at 11:15am (GMT). ... audio webcast of Hologic,s investor presentation on the investor section ... An archive of the presentation will be available for replay ...
Cached Medicine Technology:EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 2EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 3
(Date:9/19/2014)... Business Insider Australia Rates Appy Pie as a ... Appy Pie was also listed as one of the ... Yahoo . , Appy Pie a leading cloud based DIY ... minutes and it requires no coding knowledge or previous experience ... mobile operating systems, the apps created using their platform are ...
(Date:9/19/2014)... CA (PRWEB) September 19, 2014 The ... a special promotion for new patients. Throughout the month of ... dental exam with dental X-rays for just $69. A complimentary ... patients to get their teeth and gums checked and meet ... are among the best ways to protect oral health. According ...
(Date:9/19/2014)... HealthDay Reporter THURSDAY, Sept. 18, ... got a flu shot last year, so U.S. health officials ... vaccinated for the coming flu season. "It,s really unfortunate ... flu they could get," said Dr. Thomas Frieden, director of ... morning news conference. The result is lost days from ...
(Date:9/19/2014)... Quincy Bioscience is pleased to announce ... private practice in Mequon, Wis., is presenting data ... adults with mild memory problems at the ... conference on Sept. 19-20 in Hollywood, Fla. ... of the jellyfish protein apoaequorin-containing supplements. Prevagen Professional ...
(Date:9/19/2014)... LENEXA, Kan. (PRWEB) September 19, 2014 ... dedicated exclusively to healthcare providers, has been retained to ... for St. John’s Episcopal Hospital in Far Rockaway, N.Y. ... B. E. Smith has recently placed more than 900 ... Hospital is a faith-based, full service community hospital serving ...
Breaking Medicine News(10 mins):Health News:Business Insider Australia Rates Appy Pie as a top App & Game Building Platform 2Health News:Encino Esthetic Dental Group is Now Offering a Special Promotion for New Patients 2Health News:Almost Everyone Needs a Flu Shot: CDC 2Health News:Almost Everyone Needs a Flu Shot: CDC 3Health News:Prevagen Research Presented at Healthcare Practitioner Conference 2Health News:St. John’s Episcopal Hospital Retains B. E. Smith to Recruit New COO 2Health News:St. John’s Episcopal Hospital Retains B. E. Smith to Recruit New COO 3
... to the brain can be devastating. When brain cells die, ... glutamate floods the surrounding areas, overloading the cells in its ... swathes of tissue. ,Glutamate is always present ... gaps between cells. But when this chemical is released by ...
... infections in parts of Cambodia is being extended to an ... 40,000 residents, an expert said. ,Although malaria-infected mosquitoes ... the real source of the disease is people, some of ... time without showing clear symptoms. ,Moheli island, the ...
... responsible for staphylococcus infections can kill infected patients in ... by the name of PVL or otherwise called Panton ... and harm the healthy tissue as well. ... infections. This is normally found in the skin or ...
... showed reasonable resistance to Tamiflu, an antiviral, in two Egyptians who ... the medical community. ,The report also states that the ... in 2005. The occurrence of this strain in Egypt reveals that ... Tamiflu by the birdflu virus has not changed the WHO stance ...
... Center researchers have identified an approach to enhance the ... shown impressive efficacy in the treatment of chronic myelogenous ... a cancer of the bone marrow caused by a ... common forms of leukemia. Imatinib mesylate (Gleevec) is a ...
... is probing the link between breast density and its implication ... novel study on 1,112 women has brought to the fore, ... with dense breasts. The study revealed that, those with dense ... breast cancer, compared to women with fatty tissue in the ...
Cached Medicine News:Health News:New Method May Treat Brain Injuries 2Health News:Chinese Scientists Take Malaria Fight to Africa 2Health News:New Strategy for the Treatment of CML 2Health News:New Strategy for the Treatment of CML 3
Yasargil clip applying forceps Mini. Stainless steel jaw....
Round tip, sharp all around, angled....
Operating microscope with motorized zoom and variable focus up to 405 mm....
... microscope provides surgeons with brighter, crisper, magnified ... ideal for many minimally invasive spine procedures. ... every point of contact. The first graphical ... microscope allows intuitive user guidance similar to ...
Medicine Products: